[
  {
    "ts": null,
    "headline": "Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Just Way Too Hated’",
    "summary": "We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the […]",
    "url": "https://finnhub.io/api/news?id=ced4a25fca3d910ac7f6ebc9575b5eea8979753a4f5617d604267933f40c46c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731970802,
      "headline": "Jim Cramer Says Merck & Co., Inc. (MRK) Is ‘Just Way Too Hated’",
      "id": 131461941,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the […]",
      "url": "https://finnhub.io/api/news?id=ced4a25fca3d910ac7f6ebc9575b5eea8979753a4f5617d604267933f40c46c5"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock rises Monday, still underperforms market",
    "summary": "Merck & Co. Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=0c7335fe67efd1b1dd0806789c7134cee29fdfbd8d5f3fa13637650ceb8cc10c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731947700,
      "headline": "Merck & Co. Inc. stock rises Monday, still underperforms market",
      "id": 131473537,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=0c7335fe67efd1b1dd0806789c7134cee29fdfbd8d5f3fa13637650ceb8cc10c"
    }
  },
  {
    "ts": null,
    "headline": "Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?",
    "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 […]",
    "url": "https://finnhub.io/api/news?id=012eb14070806b353ac7155b243b49d2380f40903d1bd0b8602552b06cce709d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731941364,
      "headline": "Is Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?",
      "id": 131461942,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 […]",
      "url": "https://finnhub.io/api/news?id=012eb14070806b353ac7155b243b49d2380f40903d1bd0b8602552b06cce709d"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug",
    "summary": "Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.",
    "url": "https://finnhub.io/api/news?id=092bab734b2159dce242127c8491d608cf60261bd0401e19777919d175caa6e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731916438,
      "headline": "Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug",
      "id": 131461944,
      "image": "https://imgproxy.divecdn.com/kEoSswhMs3cDuPgdcev9AV7mwO8LqlhhCBBhiQYOKdI/g:nowe:0:36/c:594:336/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL2dldHR5aW1hZ2VzLTcyNTYxMTYxLTU5NHg1OTQuanBn.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.",
      "url": "https://finnhub.io/api/news?id=092bab734b2159dce242127c8491d608cf60261bd0401e19777919d175caa6e2"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Positive EU CHMP Opinion for KEYTRUDA plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...",
    "url": "https://finnhub.io/api/news?id=7e7be424f07a5aa865aa8804c2f3508ef329d6a5a80afdbc9544fa68ce56c600",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731913449,
      "headline": "Merck Receives Positive EU CHMP Opinion for KEYTRUDA plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma",
      "id": 131439909,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion...",
      "url": "https://finnhub.io/api/news?id=7e7be424f07a5aa865aa8804c2f3508ef329d6a5a80afdbc9544fa68ce56c600"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
    "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731903372,
      "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
      "id": 131438224,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/601800909/image_601800909.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91"
    }
  },
  {
    "ts": null,
    "headline": "Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November",
    "summary": "I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.",
    "url": "https://finnhub.io/api/news?id=a17e850a03d211ec74e1268d17f8ffbea7a0baa516edc4f0309e99b7308b1f0a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731896594,
      "headline": "Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November",
      "id": 131437317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.",
      "url": "https://finnhub.io/api/news?id=a17e850a03d211ec74e1268d17f8ffbea7a0baa516edc4f0309e99b7308b1f0a"
    }
  }
]